Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study (2023)
- Authors:
- Autor USP: PEREIRA, JULIANA - FM
- Unidade: FM
- DOI: 10.1182/bloodadvances.2023010330
- Subjects: LINFOMA; INFECÇÕES POR VÍRUS DE DNA; INIBIDORES DE ENZIMAS; APOPTOSE
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Blood advances
- ISSN: 2473-9529
- Volume/Número/Paginação/Ano: v. 7, n. 20, p. 6339-6350, 2023
- Este periódico é de acesso aberto
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: gold
- Licença: cc-by-nc-nd
-
ABNT
HAVERKOS, Bradley et al. Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study. Blood advances, v. 7, n. 20, p. 6339-6350, 2023Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/57344. Acesso em: 29 set. 2024. -
APA
Haverkos, B., Alpdogan, O., Baiocchi, R., Brammer, J. E., Feldman, T. A., Capra, M., et al. (2023). Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study. Blood advances, 7( 20), 6339-6350. doi:10.1182/bloodadvances.2023010330 -
NLM
Haverkos B, Alpdogan O, Baiocchi R, Brammer JE, Feldman TA, Capra M, Brem EA, Nair S, Scheinberg P, Pereira J. Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study [Internet]. Blood advances. 2023 ; 7( 20): 6339-6350.[citado 2024 set. 29 ] Available from: https://observatorio.fm.usp.br/handle/OPI/57344 -
Vancouver
Haverkos B, Alpdogan O, Baiocchi R, Brammer JE, Feldman TA, Capra M, Brem EA, Nair S, Scheinberg P, Pereira J. Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study [Internet]. Blood advances. 2023 ; 7( 20): 6339-6350.[citado 2024 set. 29 ] Available from: https://observatorio.fm.usp.br/handle/OPI/57344 - CD4+ lymphocytes in asymptomatic HTLV-1 carriers present cell cycle arrest in GO/G1 phase
- Expression of CysLTR1 and 2 in Maturating Lymphocytes of Hyperplasic Tonsils Compared to Peripheral Cells in Children
- Macrophage migration inhibitory factor and chemokine RANTES in young pediatric patients with congenital cardiac communications: relation to hemodynamic parameters and the presence of Down syndrome
- Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma
- Comparison between R-CHOP vs R-CHOP plus etoposide in untreated patients with primary mediastinal B-cell lymphoma: Preliminary findings
- 18 F-FDG pet interim and determination of cellular origin by immunohistochemistry identify a group of very good prognosis in patients with diffuse large B cell lymphoma in the rituximab era
- Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study(*)
- Follicular lymphoma: refining prognostic models and impact of pod-24 in clinical outcomes
- Factors associated with survival in patients with lymphoma and HIV
- Time-to-treatment of diffuse large B-cell lymphoma in São Paulo
Informações sobre o DOI: 10.1182/bloodadvances.2023010330 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
